Jordan R. Barrett

This paper designs de novo minibinders that inhibit blood-stage malaria replication with nanomolar potency by targeting the RH5-basigin interaction.

The paper identifies synergistic antibody interactions against the malaria protein RIPR, showing how combinations of antibodies targeting specific domains inhibit parasite invasion.

The paper identifies synergistic non-neutralizing antibodies against PfRH5 that enhance malaria parasite growth inhibition when combined with neutralizing antibodies.

The paper identifies potent neutralizing antibodies against the malaria antigen RH5 from natural infection, showing they target similar epitopes as vaccine-induced antibodies.

The paper characterizes human antibodies against PfRH5, identifies key features of potent inhibitors, and demonstrates their prophylactic potential against malaria.

This paper develops a stabilized RH5 VLP vaccine that induces improved anti-malarial antibodies compared to a soluble protein vaccine in preclinical studies.

This paper develops a combination malaria vaccine targeting the RCR-complex by fusing epitopes from RIPR to CyRPA, improving in vitro growth inhibition compared to RH5.1 alone.